Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
Part of paid clinical trials in Stanford, California.
- Sponsor
- Farshad Moradi
- Study ID
- NCT06568783
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Refractory Dermatomyostitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- [18F]-FAPI-74 — DRUG\[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
Study Details
This study proposes the use of a PET isotope, \[18F\]-Fibroblast Activation Protein Inhibitor-74, for a prospective single-center, single-arm study using MRI imaging for participants with Refractory Dermatomyostitis.
Key Dates
- Start date
- Dec 31, 2024
- Status verified
- Nov 2024
- Primary completion
- Oct 31, 2027
- Completion
- Oct 31, 2028
Study Design
- Enrollment
- 21 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: [18F]-FAPI-74 PET/ MRIParticipant receive \[18F\]-FAPI-74 injection and approximately 45-60 minutes later receive a MRI scan from vertex to legs, followed by a static PET emission scan over the same area.
Primary Outcome Measure
Rate of [18F]-FAPI-74 uptake. [ Time Frame: up to 1 hour ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University | Stanford | California | 94304 | - |
Find similar trials in Stanford, CA
By research site